Spruce Street Capital LP
Clone Performance
Feb 2026–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 100% of reported value on average across 3 quarters. Past performance does not predict future results.
Portfolio Concentration
30 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 97.5% | $497,196,250 |
| Financial Services | 2.5% | $12,487,600 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | +1,066,824 | 3,693,931 | $12,596,304 | |
| ALKS | Alkermes plc. | +225,884 | 543,876 | $28,499,102 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | +157,007 | 918,070 | $58,710,576 | |
| ENTA | Enanta Pharmaceuticals Inc | +156,133 | 1,088,731 | $15,873,697 | |
| RLMD | Relmada Therapeutics, Inc. | +129,214 | 6,391,328 | $44,227,989 | |
| SVRA | Savara Inc | +69,401 | 3,452,576 | $21,267,868 | |
| PCVX | Vaxcyte, Inc. | +60,338 | 306,047 | $17,790,512 | |
| ANRO | Alto Neuroscience, Inc. | +27,837 | 1,353,047 | $35,706,910 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | −18,458 | 354,816 | $34,587,463 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IFRX | InflaRx N.V. | 5,352,198 | $11,988,923 | |
| RACC | Research Alliance Corp III | 500,000 | $5,350,000 | |
| ZLAB | Zai Lab Ltd | 279,110 | $5,303,090 | |
| ACHV | Achieve Life Sciences, Inc. | 736,637 | $4,810,239 | |
| JATT | JATT II Acquisition Corp. | 160,000 | $1,817,600 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| KNSA |
Kiniksa Pharmaceuticals International, plc
Healthcare
|
Added | 918,070 | $58,710,576 | 11.52% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Held | 2,984,125 | $55,832,978 | 10.95% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Held | 1,376,159 | $44,663,240 | 8.76% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Added | 6,391,328 | $44,227,989 | 8.68% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Added | 1,353,047 | $35,706,910 | 7.01% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Reduced | 354,816 | $34,587,463 | 6.79% | |
| ALKS |
Alkermes plc.
Healthcare
|
Added | 543,876 | $28,499,102 | 5.59% | |
| SVRA |
Savara Inc
Healthcare
|
Added | 3,452,576 | $21,267,868 | 4.17% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Added | 306,047 | $17,790,512 | 3.49% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Held | 329,006 | $16,697,054 | 3.28% | |
| ENTA |
Enanta Pharmaceuticals Inc
Healthcare
|
Added | 1,088,731 | $15,873,697 | 3.11% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
Added | 3,693,931 | $12,596,304 | 2.47% | |
| IFRX |
InflaRx N.V.
Healthcare
|
NEW | 5,352,198 | $11,988,923 | 2.35% | |
| SRZN |
Surrozen, Inc./DE
Healthcare
|
Held | 432,040 | $11,211,438 | 2.20% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 392,574 | $11,047,032 | 2.17% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 4,059,054 | $9,944,682 | 1.95% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Held | 1,655,500 | $9,188,025 | 1.80% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
Held | 2,198,502 | $8,574,157 | 1.68% | |
| ANTX |
AN2 Therapeutics, Inc.
Healthcare
|
Held | 1,661,073 | $8,039,593 | 1.58% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Held | 422,543 | $7,740,987 | 1.52% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Held | 3,581,603 | $7,270,654 | 1.43% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 500,000 | $5,350,000 | 1.05% | |
| HLXC |
Helix Acquisition Corp. III
Financial Services
|
Held | 500,000 | $5,320,000 | 1.04% | |
| ZLAB |
Zai Lab Ltd
Healthcare
|
NEW | 279,110 | $5,303,090 | 1.04% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
NEW | 736,637 | $4,810,239 | 0.94% | |
| LXEO |
Lexeo Therapeutics, Inc.
Healthcare
|
Held | 928,593 | $4,322,600 | 0.85% | |
| ALEC |
Alector, Inc.
Healthcare
|
Held | 2,101,068 | $4,223,146 | 0.83% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 393,701 | $3,618,112 | 0.71% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
Held | 231,585 | $3,459,879 | 0.68% | |
| JATT |
JATT II Acquisition Corp.
Financial Services
|
NEW | 160,000 | $1,817,600 | 0.36% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.